Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Breo

- PMLiVE

Teva’s generic Nexium wins US approval

FDA backs copy of AstraZeneca’s heartburn drug

- PMLiVE

Indian generics firm GVK set to be hit with European sales ban

EU regulator raises concerns on conduct of drug studies in India

- PMLiVE

Regulators to improve cooperation on generic drugs

EMA to spearhead information sharing initiative

Lannett appoints Teva’s Michael Bogda as president

He served as VP of technical operations in for Teva’s Americas division

- PMLiVE

UCB’s $1.53bn generics sale falls through

Advent and Avista Capita back away from bid to acquire Kremers Urban due to unanticipated conflict in timing

- PMLiVE

Teva board elects Yitzhak Peterburg as chairman

He succeeds Phillip Frost

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

- PMLiVE

UCB to sell its US generics business for $1.5bn

Advent International and Avista Capital Partners will take control of Kremers Urban Pharmaceuticals

Teva Pharma logo

Cuts help Teva raise profits, despite flat sales

Earnings attributed largely to firm’s generics business

The pharma business environment in the US

Tighter regulations, more pricing controls and increased international competition will drive market improvements

- PMLiVE

GSK to sell off part of its HIV venture ViiV Healthcare

And sets out new restructure programme as US Seretide sales hit

Teva Pharma logo

Teva scales back R&D as Copaxone competition looms

Copaxone accounts for almost 40% of its revenue

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links